Belzutifan

COMPOSITION:

Each film-coated tablet contains Belzutifan ……………………………………………… 40mg.

INDICATION:

LuciBelzu is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

DOSAGE AND USE:

The recommended dosage of LuciBelzu is 120 mg administered orally once daily with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciBelzu during Pregnancy and Lactation.